Literature DB >> 31559889

Successful treatment of central nervous system involved Erdheim-Chester disease by intermediate-dose cytarabine as first-line therapy.

Ji-Nuo Wang1, Yu Qiu1, Na Niu2, Yan Zhang1, Jian Li1, Dao-Bin Zhou1, Xin-Xin Cao1.   

Abstract

Entities:  

Year:  2019        PMID： 31559889     DOI： 10.1080/0284186X.2019.1670355

Source DB:  PubMed          Journal:  Acta Oncol        ISSN： 0284-186X            Impact factor:   4.089


× No keyword cloud information.
  2 in total

1.  Erdheim-Chester Disease and Acute Myeloid Leukemia with Mutated NPM1 in a Patient with Clonal Hematopoiesis: A Case Report.

Authors:  Andreas Mavrogenis; Vasiliki Pappa; Periklis G Foukas; Sotirios G Papageorgiou; Aspasia Divane; Maria Roumelioti; Christine Kottaridi; Anthi Bouchla; Alexandros Georgakopoulos; Fotini Ieremiadou; Aggeliki Daraki; Efthymia Bazani; Thomas P Thomopoulos; Sofia Chatziioannou; Panayiotis Panayiotidis; Ioannis G Panayiotides
Journal:  Onco Targets Ther       Date:  2020-11-16       Impact factor: 4.147

2.  Intermediate-dose cytarabine is an effective therapy for adults with non-Langerhans cell histiocytosis.

Authors:  Ting Liu; Hua-Cong Cai; Hao Cai; Miao Chen; Wei Zhang; Jian Li; Dao-Bin Zhou; Xin-Xin Cao
Journal:  Orphanet J Rare Dis       Date:  2022-02-07       Impact factor: 4.123
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.